63 related articles for article (PubMed ID: 30850562)
1. Endostatin and Oxaliplatin-Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study.
Li W; Chen P; Zhang N; Song T; Wu S
Oncologist; 2019 Apr; 24(4):461-e136. PubMed ID: 30850562
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
[TBL] [Abstract][Full Text] [Related]
3. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial.
Pöttgen C; Gkika E; Stahl M; Abu Jawad J; Gauler T; Kasper S; Trarbach T; Herrmann K; Lehmann N; Jöckel KH; Lax H; Stuschke M
Radiat Oncol; 2021 Mar; 16(1):59. PubMed ID: 33757534
[TBL] [Abstract][Full Text] [Related]
4. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.
Liu C; Sun H; Huang W; Wang Z; Fu C; Han D; Zhao Q; Wu X; Li B
Front Immunol; 2023; 14():1193394. PubMed ID: 37325650
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity.
Ristau J; Thiel M; Katayama S; Schlampp I; Lang K; Häfner MF; Herfarth K; Debus J; Koerber SA
Radiat Oncol; 2021 Feb; 16(1):23. PubMed ID: 33522923
[TBL] [Abstract][Full Text] [Related]
6. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.
Crosby T; Hurt CN; Falk S; Gollins S; Staffurth J; Ray R; Bridgewater JA; Geh JI; Cunningham D; Blazeby J; Roy R; Maughan T; Griffiths G; Mukherjee S
Br J Cancer; 2017 Mar; 116(6):709-716. PubMed ID: 28196063
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy Alone in Esophageal Squamous Cell Carcinoma Induction chemotherapy in Esophageal Squamous Cell Carcinoma.
Hosseini Toudeshki S; Garousi M; Arefpour AM; Fadavi P; Basi A; Foroughi A; Javadinia SA
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1183-1188. PubMed ID: 38679976
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Patients With Inoperable Esophageal Squamous Cell Carcinoma Undergoing Curative-Intent Concurrent Chemoradiotherapy.
Chang CL; Lin KC; Chen WM; Shia BC; Wu SY
J Thorac Oncol; 2024 May; 19(5):818-828. PubMed ID: 38154513
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus.
Zhong Z; Gu X; Zhang Z; Wang D; Qing Y; Li M; Dai N
Br J Radiol; 2012 Nov; 85(1019):e1104-9. PubMed ID: 22898155
[TBL] [Abstract][Full Text] [Related]
10. Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.
Zhao Z; Wen Y; Liao D; Miao J; Gui Y; Cai H; Chen Y; Wei M; Jia Q; Tian H; Sun M; Zhang Y; Feng G; Du X
Oncologist; 2020 Dec; 25(12):e1900-e1908. PubMed ID: 32864805
[TBL] [Abstract][Full Text] [Related]
11. Elective nodal irradiation versus involved-field irradiation for stage II-IV cervical esophageal squamous cell carcinoma patients undergoing definitive concurrent chemoradiotherapy: a retrospective propensity study with 8-year survival outcomes.
Wang J; Wu Y; Zhang W; Chen Y; Liu Q; Jing S; Zhang J; Wu F; Wang J; Qiao X
Radiat Oncol; 2023 Aug; 18(1):142. PubMed ID: 37641149
[TBL] [Abstract][Full Text] [Related]
12. Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin.
Yada M; Yamamoto S; Honma Y; Hirano H; Okita N; Shoji H; Iwasa S; Takashima A; Nagahara A; Kato K
In Vivo; 2024; 38(2):761-766. PubMed ID: 38418117
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study.
Yu N; Cheng G; Li J; Liang J; Zhang T; Deng L; Liu W; Wang J; Zhai Y; Wang W; Xiao Z; Zhou Z; Chen D; Feng Q; Bi N; Wang X
Curr Cancer Drug Targets; 2023; 23(8):653-662. PubMed ID: 36924100
[TBL] [Abstract][Full Text] [Related]
14. Individualized treatment decision model for inoperable elderly esophageal squamous cell carcinoma based on multi-modal data fusion.
Huang Y; Huang X; Wang A; Chen Q; Chen G; Ye J; Wang Y; Qin Z; Xu K
BMC Med Inform Decis Mak; 2023 Oct; 23(1):237. PubMed ID: 37872517
[TBL] [Abstract][Full Text] [Related]
15. Consolidation chemotherapy after definitive concurrent chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma: a multicenter non-inferiority phase III randomized clinical trial.
Fan C; Wang X; Zheng X; Sun Y; Ye K; Jiang Y; Liu X; Xu W; Liu Y; Yang Y; Liu J; Jiang Q; He C; Wu X; Nie X; Zhang J; Tan B; Wang W; Zhang Y; Feng Z; Yang C; Lu Y; Liu H; Chen X; Xu J; Liu F; Zheng X; Wang J; Wu S; Chen G; Zhang Y; Jin L; Ge H
BMC Cancer; 2024 Mar; 24(1):321. PubMed ID: 38454345
[TBL] [Abstract][Full Text] [Related]
16. Value of blood oxygenation level-dependent magnetic resonance imaging in early evaluation of the response and prognosis of esophageal squamous cell carcinoma treated with definitive chemoradiotherapy: a preliminary study.
Zheng H; Zhang H; Zhu Y; Wei X; Liu S; Ren W
BMC Med Imaging; 2024 Jan; 24(1):18. PubMed ID: 38216885
[TBL] [Abstract][Full Text] [Related]
17. Chemoradiotherapy and Increased Prescription Dose in Esophageal Squamous Cell Cancer: A Retrospective Study.
Pan X; Liao M; Ma H; Jiang X; Huang H; Wei M; Li Q
Biomed Res Int; 2021; 2021():3834040. PubMed ID: 33628778
[TBL] [Abstract][Full Text] [Related]
18. Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma.
Xie R; Cai Q; Chen T; Huang H; Chen C
Front Oncol; 2024; 14():1303068. PubMed ID: 38344202
[TBL] [Abstract][Full Text] [Related]
19. Esophageal chemoradiotherapy with concurrent nivolumab: Pilot results in the palliative treatment of oligometastatic disease.
Day F; Sridharan S; Johnson C; Quah GT; Mallesara G; Kumar M; Poulter AL; Morrison A; van der Westhuizen A; Fraser A; Oldmeadow C; Martin J
Asia Pac J Clin Oncol; 2024 Jun; 20(3):416-422. PubMed ID: 38512856
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of clinical outcome of 100 inoperable oral cavity carcinoma treated with definitive concurrent chemoradiotherapy with or without induction chemotherapy.
Mishra VK; Gandhi AK; Rastogi M; Verma R; Khurana R; Hadi R; Sharma V; Agarwal A; Srivastava AK
Ecancermedicalscience; 2023; 17():1630. PubMed ID: 38414943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
